-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

Benzinga·09/28/2026 18:02:03
Diffusion vocale
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.